Solid Biosciences Inc. (SLDB) Earnings History
Annual and quarterly earnings data from 2015 to 2025
Loading earnings history...
SLDB EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
SLDB Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | 100.0% | -1315.2% | -1062.3% |
| 2021 | 100.0% | -530.5% | -530.0% |
Download Data
Export SLDB earnings history in CSV or JSON format
Free sign-in required to download data
Solid Biosciences Inc. (SLDB) Earnings Overview
As of May 8, 2026, Solid Biosciences Inc. (SLDB) reported trailing twelve-month net income of -$167M, reflecting +35.0% year-over-year growth. The company earned $-1.77 per diluted share over the past four quarters.
Looking at the long-term picture, SLDB's historical earnings data spans multiple years. The company achieved its highest annual net income of -$6M in fiscal 2015.
Solid Biosciences Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SRPT ($65M net income, -32.5% margin), CRSP (-$569M net income, -16569.8% margin), SGMO (-$109M net income, -169.4% margin), SLDB has comparable earnings metrics. Compare SLDB vs SRPT →
SLDB Earnings vs Peers
Earnings metrics vs comparable public companies
SLDB Historical Earnings Data (2015–2025)
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$174M | -39.8% | -$179M | $-1.99 | - | - |
| 2024 | -$125M | -29.9% | -$130M | $-3.06 | - | - |
| 2023 | -$96M | -11.7% | -$104M | $-4.83 | - | - |
| 2022 | -$86M | -19.1% | -$106M | $-10.10 | -1062.3% | -1315.2% |
| 2021 | -$72M | +18.2% | -$72M | $-10.14 | -530.0% | -530.5% |
| 2020 | -$88M | +24.7% | -$86M | $-25.50 | - | - |
| 2019 | -$117M | -56.7% | -$119M | $-43.05 | - | - |
| 2018 | -$75M | -43.5% | -$76M | $-33.73 | - | - |
| 2017 | -$52M | -142.0% | -$55M | $-24.26 | - | - |
| 2016 | -$22M | -237.8% | -$26M | $-16.80 | - | - |
See SLDB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SLDB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SLDB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSLDB — Frequently Asked Questions
Quick answers to the most common questions about buying SLDB stock.
Is SLDB growing earnings?
SLDB EPS is $-1.77, with earnings growth accelerating to +35.0%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-167M.
What are SLDB's profit margins?
Solid Biosciences Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are SLDB's earnings?
SLDB earnings data spans 2015-2025. The accelerating earnings trend is +35.0% YoY. Historical data enables comparison across business cycles.